{'fraction_non_alphanumeric': 0.029354207436399216, 'fraction_numerical': 0.03131115459882583, 'mean_word_length': 4.9476744186046515, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Breast implant‐associated anaplastic large cell lymphoma in a patient with Li–Fraumeni syndrome

Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare form of ALK-negative ALCL, usually presenting as an accumulation of seroma fluid between the implant itself and the surrounding fibrous capsule.1 It was first described in 1997.2 From 1997 to 2012, the United States Food and Drug Administration reported a total of 60 registered instances of BIA-ALCL with a mean interval to lymphoma diagnosis of 10.9 years.3-5 It is estimated that 1 of 500,000 women receiving breast implants will develop BIA-ALCL.5, 6 Recent studies have suggested that patients can be managed conservatively, by drainage of the fluid and removal of the implant and capsule, if no invasion of the capsule or breast tissue is identified. 3, 7 However, some patients manifest invasion of the capsule, and involvement of breast, lymph nodes, or more rarely distant sites. The risk factors for progression are not fully delineated.